Dehydrocostus lactone suppresses ox-LDL-induced attachment of monocytes to endothelial cells

Kai Wang1, Aihua Zhou1, Miaohua Ruan1

  • 1Department of Pediatrics, The First Affiliated Hospital of Wenzhou Medical University Wenzhou 325000, Zhejiang Province, China.

Insights

Dehydrocostus lactone (DHL) shows promise in treating atherosclerosis. It inhibits oxidized low-density lipoprotein (ox-LDL)-induced inflammation and monocyte attachment to the endothelium, potentially preventing plaque formation.

Area of Science:

  • Cardiovascular Science
  • Pharmacology
  • Molecular Biology

Background:

  • Atherosclerosis is a prevalent cardiovascular disease with complex, poorly understood pathogenesis.
  • Endothelial dysfunction, oxidative stress, and inflammation are key contributors to atherogenesis.
  • Fatty plaque formation on arterial endothelium is a hallmark of advanced atherosclerosis.

Purpose of the Study:

  • To investigate the therapeutic potential of dehydrocostus lactone (DHL) in treating atherosclerosis.
  • To elucidate the molecular mechanisms underlying DHL's effects on endothelial cells.
  • To evaluate DHL's efficacy against oxidized low-density lipoprotein (ox-LDL)-induced endothelial dysfunction.

Main Methods:

  • Assessing DHL's effect on VCAM-1 and E-selectin expression induced by ox-LDL.
  • Analyzing downstream effects of VCAM-1 and E-selectin, including monocyte attachment and cytokine release.
  • Investigating DHL's impact on KLF2 expression, a regulator of endothelial adhesion molecules.

Main Results:

  • DHL significantly inhibited ox-LDL-induced VCAM-1 and E-selectin expression.
  • DHL reduced monocyte-to-endothelial cell attachment and the release of proinflammatory cytokines (TNF-α, MCP-1, HMGB1).
  • DHL restored the expression of KLF2, an important regulator of endothelial activation.

Conclusions:

  • Dehydrocostus lactone (DHL) demonstrates significant potential as a prophylactic or therapeutic agent against atherosclerosis.
  • DHL acts by inhibiting ox-LDL-induced endothelial activation and monocyte adhesion.
  • DHL's mechanism involves regulating VCAM-1, E-selectin, and KLF2 expression, offering a novel treatment strategy.